Jazz Pharmaceuticals JAZZ announced that it has entered into a definitive agreement to acquire all the outstanding shares of ...

Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

H.C. Wainwright downgraded Chimerix (CMRX) to Neutral from Buy after the company agreed to be acquired for $8.55 per share in cash by Jazz Pharmaceuticals (JAZZ). The total consideration of ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) and Chimerix (Nasdaq: CMRX) (“Chimerix”), today announced the companies have entered into a definitive agreement for Jazz to acquire ...

In a deal worth approximately $935m, Jazz Pharmaceuticals is set to acquire Chimerix, a biotechnology company developing ...

Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately ...

Ireland-headquartered Jazz Pharmaceuticals has entered into a definitive agreement to acquire US biopharma company Chimerix ...

From 2019-2023, North Carolina increased the number of life sciences business establishments by 43%. To learn more in the ...

JonesResearch downgraded Chimerix (CMRX) to Hold from Buy with an $8.55 price target after Jazz Pharmaceuticals (JAZZ) announced a deal to ...

Jazz Pharmaceuticals plc is buying Chimerix Inc. for $8.55 a share in cash, bringing the deal in at about $935 million. Jazz expands its cancer pipeline with the new acquisition’s lead candidate, ...

The stock makes the NASDAQ top percentage gainers list on acquisition news today, currently trading at $8.44, up 3.48, ...

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are ...